4. Guébre-Xabier M, Hammond SA, Epperson DE, Yu J, Ellingsworth L, Glenn GM. Immunostimulant patch containing heat labile
enterotoxin from E. coli enhances immune responses to injected influenza vaccine through activation of skin dendritic cells. J. Virol. 2003;77(9):5218–5225.
5. Glenn, GM, Frech, SA, Kenney, RT, Ellingsworth, LR. Transcutaneous immunization: antigen and adjuvant delivery to the
skin. In: Bronaugh RL, Maibach HI, editors. Percutaneous absorption: drugs, cosmetics, mechanisms, methods, 4th ed. New York:
Informa Healthcare; 2005.
6. Glenn GM, Kenney RT. Mass vaccination: solutions in the skin. Curr. Top. Microbiol. Immunol. 2006;304:247–268.
7. Glenn GM, Kenney RT. Transcutaneous immunization. In: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good M, editors. New generation
vaccines, 3rd ed. New York: Marcel Dekker, Inc.; 2003.
8. Belyakov IM, Hammond SA, Ahlers JD, Glenn JA, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective
immunity by migration of primed skin dendritic cells. J. Clin. Invest. 2004;113:998–1007.
9. Glenn GM, Kenney RT, Ellingsworth LR, Frech SA, Hammond SA, Zoeteweij, JP. Transcutaneous immunization and immunostimulant
strategies: capitalizing on the immunocompetence of the skin. Expert Rev. Vaccines 2003;2:253–267.
10. Glenn GM, Kenney RT, Hammond SA, Ellingsworth LR. Transcutaneous immunization and immunostimulant strategies. Immunol.
Allergy Clin. North Am. 2003;23:787–813.
11. Hammond SA, Walwender D, Alving CR, Glenn GM. Transcutaneous immunization: T-cell responses and boosting of existing
immunity. Vaccine 2001;19:2701–2707.
12. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: A human vaccine delivery
strategy using a patch. Nature Med. 2000;6:1403–1406.
13. Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR Alving CR. Transcutaneous immunization with bacterial ADP-ribosylating
exotoxins as antigens and adjuvants. Infect. Immun. 1999;67:1100–1106.
14. Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM, Frech SA. Safety and immunogenicity of an enterotoxigenic
Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect.
Immun. 2007;75:2163–2170.
15. Frech SA, Kenney RT, Spyr CA, Lazar H, Viret JF, Herzog C, Glück R, Glenn GM. Improved immune responses to influenza
vaccination in the elderly using an immunostimulant patch. Vaccine 2005;23(7):946–50.
16. Sack DA, Sack RB. Test for enterotoxigenic Escherichia coli using Y1 adrenal cells in miniculture. Infect. Immun. 1975;11:334–336.
17. US Food and Drug Administration. Guidance for industry. Stability testing of drug substances and drug products. Rockville,
MD; June 1998.
18. Lucas TI, Bishara RH, Seevers RH. A stability program for the distribution of drug products. Pharm. Technol. 2004:68–73.
19. International Conference on Harmonization. Q1D, Bracketing and matrixing designs for stability testing of new drug substances
and products. Geneva, Switzerland; Feb. 2002.
20. International Conference on Harmonization Code Q1A(R2). Stability testing of new drug substances and products. Geneva,
Switzerland; Feb.2003.
21. Water activity. In: Official methods of analysis of the AOAC. 13th ed. AOAC International 32.004–32.009; 1980.
22. Troller JA, Bernard DT, Scott VN. Measurement of water activity. In: Speck ML, editor. The compendium of methods for
the microbiological examination of food. Washington, D.C.: American Public Health Association, 1984. p. 124–134
|
